Biomerica, Inc. (BMRA)
NASDAQ: BMRA · Real-Time Price · USD
0.355
-0.017 (-4.57%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide.

The company’s diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations.

It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.

The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H.

Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria.

In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19.

The company was incorporated in 1971 and is headquartered in Irvine, California.

Biomerica, Inc.
Biomerica logo
Country United States
Founded 1971
Industry Medical Devices
Sector Healthcare
Employees 64
CEO Zackary Irani

Contact Details

Address:
17571 Von Karman Avenue
Irvine, California 92614
United States
Phone (949) 645-2111
Website biomerica.com

Stock Details

Ticker Symbol BMRA
Exchange NASDAQ
Fiscal Year June - May
Reporting Currency USD
CIK Code 0000073290
CUSIP Number 09061H307
ISIN Number US09061H3075
Employer ID 95-2645573
SIC Code 2835

Key Executives

Name Position
Zackary S. Irani Chief Executive Officer and Director
Allen C. Barbieri Executive Vice-Chairman of the Board and Corporate Secretary
Gary Lu CPA Principal Accounting Officer and Chief Financial Officer
Lucy Liu Ph.D. Director of Manufacturing and Technical Operations
Robert W. Carlson Chief Commercial Officer

Latest SEC Filings

Date Type Title
Oct 15, 2024 10-Q Quarterly Report
Sep 30, 2024 DEF 14A Other definitive proxy statements
Sep 20, 2024 PRE 14A Other preliminary proxy statements
Aug 28, 2024 10-K Annual Report
Jun 28, 2024 8-K Current Report
May 10, 2024 424B5 Filing
May 10, 2024 8-K Current Report
Apr 12, 2024 10-Q Quarterly Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals